Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 4/20 | 0.43 |
| ▸ | RAF1 | P04049 | 2/20 | 0.43 |
| ▸ | ARAF | P10398 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 11/20 | 0.42 |
| ▸ | IDH2 | P48735 | 2/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3767003 | 0.91 | BRAF (0.42) | BRAFRAF1ARAFKDR | |
| SCHEMBL3768545 | 0.77 | BRAF (0.51) | BRAFRAF1KDRAURKA | |
| SCHEMBL3760992 | 0.77 | KDR (0.53) | BRAFKDRKIT | |
| SCHEMBL3834284 | 0.76 | RET (0.43) | BRAFRAF1KDRIDH2AURKA | |
| SCHEMBL9902789 | 0.76 | EPHX2 (0.54) | BRAFRAF1KDRAURKAPDGFRA | |
| SCHEMBL9903598 | 0.73 | BRAF (0.52) | BRAFRAF1ARAFKDRAURKA | |
| SCHEMBL3761347 | 0.72 | CA12 (0.52) | BRAFKDRAURKACDK1PDGFRB | |
| SCHEMBL3833243 | 0.68 | RET (0.42) | BRAFKDRIDH2SCN8ASCN10A | |
| SCHEMBL2333691 | 0.68 | KDR (0.47) | BRAFKDRPDGFRBPDGFRAFLT1 | |
| SCHEMBL2333081 | 0.68 | ALDH1A1 (0.48) | BRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809629-B1 | N,N'-diphenyl urea derivatives suitable for the treatment of tumours, eye diseases, inflammation and diseases of the immune system | MERCK PATENT GMBH (DE) | 2012-06-13 | — | — | EP | claimed |
| US-7846927-B2 | N,N′-diphenylurea derivatives suitable as kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-12-07 | — | — | US | claimed |
| US-20070293488-A1 | tyrosine kinase inhibitors such as 1-(2-fluoro-5-trifluoromethylphenyl)-3-[4-(5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-4-ylamino)phenyl]urea, used as antitumor or anticarcinogenic agents or for the treatment of psoriasis, arthritis, retinopathy or dermatitis | MERCK PATENT GMBH (DE) | 2007-12-20 | — | — | US | claimed |
| US-7846927-B2 | N,N′-diphenylurea derivatives suitable as kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-12-07 | — | — | US | disclosed |
| US-20070293488-A1 | tyrosine kinase inhibitors such as 1-(2-fluoro-5-trifluoromethylphenyl)-3-[4-(5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-4-ylamino)phenyl]urea, used as antitumor or anticarcinogenic agents or for the treatment of psoriasis, arthritis, retinopathy or dermatitis | MERCK PATENT GMBH (DE) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293488-A1 | tyrosine kinase inhibitors such as 1-(2-fluoro-5-trifluoromethylphenyl)-3-[4-(5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-4-ylamino)phenyl]urea, used as antitumor or anticarcinogenic agents or for the treatment of psoriasis, arthritis, retinopathy or dermatitis | TIE1, FLT1, FER | BRAF 10/4885RAF1 12/4885ARAF 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.